IGC Pharma annual debt-to-equity ratio
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2025
IGC Pharma Debt-to-Equity Ratio Growth & History (IGC)
IGC Pharma's debt-to-equity ratio was 0.02 for fiscal 2025.
View full IGC Pharma company overviewIGC Pharma annual debt-to-equity ratio history
| Fiscal year | Period ended | Debt-to-equity ratio | Change | Growth |
|---|---|---|---|---|
| 2025 · Dec 31 | 2025-12-31 | 0.02 | — | — |
| 2025 · Mar 31 | 2025-03-31 | 0.04 | −0.01 | −20.24% |
| 2024 | 2024-03-31 | 0.05 | 0.02 | +46.44% |
| 2023 | 2023-03-31 | 0.03 | 0.01 | +26.93% |
| 2022 | 2022-03-31 | 0.03 | −0.01 | −21.96% |
| 2021 | 2021-03-31 | 0.03 | 0.01 | +39.37% |
| 2020 | 2020-03-31 | 0.02 | 0.02 | +1478.85% |
| 2019 | 2019-03-31 | 0.00 | 0.00 | — |
| 2018 | 2018-03-31 | 0.00 | −0.06 | — |
| 2017 | 2017-03-31 | 0.06 | −0.00 | −0.17% |
| 2016 | 2016-03-31 | 0.06 | −0.05 | −45.40% |
| 2015 | 2015-03-31 | 0.11 | 0.11 | — |
| 2014 | 2014-03-31 | 0.00 | 0.00 | — |
| 2013 | 2013-03-31 | 0.00 | 0.00 | — |
| 2012 | 2012-03-31 | 0.00 | −0.14 | — |
| 2011 | 2011-03-31 | 0.14 | — | — |
IGC Pharma quarterly debt-to-equity ratio
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Debt-to-equity ratio | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 · Jun 30 | 2026-06-30 | 0.00 | −0.03 | — |
| Q1 2026 · Mar 31 | 2026-03-31 | 0.00 | −0.04 | −96.12% |
| Q4 2025 · Dec 31 | 2025-12-31 | 0.02 | −0.02 | −55.22% |
| Q2 2026 · Sep 30 | 2025-09-30 | 0.02 | −0.02 | −55.46% |
| Q1 2026 · Jun 30 | 2025-06-30 | 0.03 | −0.01 | −22.06% |
| Q4 2025 · Mar 31 | 2025-03-31 | 0.04 | −0.01 | −20.24% |
| Q3 2025 | 2024-12-31 | 0.04 | 0.00 | +3.91% |
| Q2 2025 | 2024-09-30 | 0.04 | 0.01 | +40.36% |
| Q1 2025 | 2024-06-30 | 0.04 | 0.01 | +26.68% |
| Q4 2024 | 2024-03-31 | 0.05 | 0.02 | +46.44% |
| Q3 2024 | 2023-12-31 | 0.04 | 0.01 | +49.29% |
| Q2 2024 | 2023-09-30 | 0.03 | 0.00 | +8.99% |
| Q1 2024 | 2023-06-30 | 0.03 | 0.01 | +29.81% |
| Q4 2023 | 2023-03-31 | 0.03 | 0.01 | +26.93% |
| Q3 2023 | 2022-12-31 | 0.03 | 0.01 | +29.08% |
| Q2 2023 | 2022-09-30 | 0.03 | 0.01 | +26.91% |
| Q1 2023 | 2022-06-30 | 0.03 | 0.00 | +19.83% |
| Q4 2022 | 2022-03-31 | 0.03 | −0.01 | −21.96% |
| Q3 2022 | 2021-12-31 | 0.02 | −0.03 | −57.33% |
| Q2 2022 | 2021-09-30 | 0.02 | −0.03 | −54.67% |
| Q1 2022 | 2021-06-30 | 0.02 | −0.03 | −53.92% |
| Q4 2021 | 2021-03-31 | 0.03 | 0.01 | +39.37% |
| Q3 2021 | 2020-12-31 | 0.05 | 0.05 | +2940.75% |
| Q2 2021 | 2020-09-30 | 0.05 | 0.05 | +2855.00% |
| Q1 2021 | 2020-06-30 | 0.05 | 0.05 | +2990.35% |
| Q4 2020 | 2020-03-31 | 0.02 | 0.02 | +1478.85% |
| Q3 2020 | 2019-12-31 | 0.00 | 0.00 | — |
| Q2 2020 | 2019-09-30 | 0.00 | 0.00 | — |
| Q1 2020 | 2019-06-30 | 0.00 | 0.00 | — |
| Q4 2019 | 2019-03-31 | 0.00 | 0.00 | — |
| Q3 2019 | 2018-12-31 | 0.00 | 0.00 | — |
| Q2 2019 | 2018-09-30 | 0.00 | −0.06 | — |
| Q1 2019 | 2018-06-30 | 0.00 | −0.03 | — |
| Q4 2018 | 2018-03-31 | 0.00 | −0.06 | — |
| Q3 2018 | 2017-12-31 | 0.00 | −0.06 | — |
| Q2 2018 | 2017-09-30 | 0.06 | 0.01 | +24.06% |
| Q1 2018 | 2017-06-30 | 0.03 | −0.02 | −37.96% |
| Q4 2017 | 2017-03-31 | 0.06 | −0.00 | −0.17% |
| Q3 2017 | 2016-12-31 | 0.06 | −0.03 | −34.83% |
| Q2 2017 | 2016-09-30 | 0.05 | −0.01 | −23.57% |
| Q1 2017 | 2016-06-30 | 0.05 | −0.07 | −59.04% |
| Q4 2016 | 2016-03-31 | 0.06 | −0.05 | −45.40% |
| Q3 2016 | 2015-12-31 | 0.09 | 0.07 | +333.63% |
| Q2 2016 | 2015-09-30 | 0.06 | 0.04 | +159.77% |
| Q1 2016 | 2015-06-30 | 0.11 | 0.09 | +398.65% |
| Q4 2015 | 2015-03-31 | 0.11 | 0.11 | — |
| Q3 2015 | 2014-12-31 | 0.02 | 0.02 | — |
| Q2 2015 | 2014-09-30 | 0.02 | 0.02 | — |
| Q1 2015 | 2014-06-30 | 0.02 | 0.02 | — |
| Q4 2014 | 2014-03-31 | 0.00 | 0.00 | — |
| Q3 2014 | 2013-12-31 | 0.00 | −0.00 | — |
| Q2 2014 | 2013-09-30 | 0.00 | −0.01 | — |
| Q1 2014 | 2013-06-30 | 0.00 | −0.01 | — |
| Q4 2013 | 2013-03-31 | 0.00 | 0.00 | — |
| Q3 2013 | 2012-12-31 | 0.00 | −0.06 | −99.47% |
| Q2 2013 | 2012-09-30 | 0.01 | −0.13 | −91.36% |
| Q1 2013 | 2012-06-30 | 0.01 | −0.11 | −88.82% |
| Q4 2012 | 2012-03-31 | 0.00 | −0.14 | — |
| Q3 2012 | 2011-12-31 | 0.06 | — | — |
| Q2 2012 | 2011-09-30 | 0.14 | — | — |
| Q1 2012 | 2011-06-30 | 0.12 | — | — |
| Q4 2011 | 2011-03-31 | 0.14 | — | — |
IGC Pharma debt-to-equity ratio trends
Between the periods ended 2011-03-31 and 2025-12-31, IGC Pharma's debt-to-equity ratio decreased from 0.14 to 0.02, a change of −0.12. The latest reported quarter, Q2 2026 · Jun 30, shows 0.00.
About the metric
What the debt-to-equity ratio means
The debt-to-equity ratio compares interest-bearing debt with shareholders’ equity. It helps show how much debt financing a company uses relative to its accounting equity, but useful comparison levels vary by industry.
Calculation and source
How debt-to-equity is calculated
TickerStat calculates debt-to-equity as total interest-bearing debt divided by SEC-reported shareholders’ equity for the same balance-sheet date. Total liabilities are not treated as debt, and periods with non-positive equity are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review IGC Pharma source filings ↗